OXFORD NANOPORE TECHNOLOGIES - Key Persons
Job Titles:
- Chairman of Audit & Risk Committee
- Non - Executive Director
- Business Leader
Adrian is a highly regarded business leader with nearly 20 years' leadership experience at a number of FTSE 100 companies. His background encompasses a breadth of sectors including healthcare, technology, FMCG and engineering. Adrian was Chief Financial Officer at Reckitt Benckiser for seven years and held the same role at both Smith & Nephew and Invensys. He spent 18 years at GlaxoSmithKline, holding a number of senior management and financial positions. Adrian began his career at PwC, working in both audit and consultancy, and Stadtsparkasse Koeln, the German regional bank. Adrian currently serves on the Board of Sainsbury's, where he is a member of the Audit and Nomination Committees, and Oxford University Press.
Alvaro joined Oxford Nanopore in 2017 and is now heads up our global supply chain team.
Alvaro has formalised the supply chain function through upgrading systems and implementing new processes. He has developed a team with broad skills across sourcing and supplier management, warehousing, inventory management, production, demand planning and distribution.
Leading the supply chain function in a disruptive organisation, Alvaro's goal is to strengthen the business by providing best- in-class supply chain operations. This delivers competitive advantage through firm foundations and systems, solid processes and well trained teams - all primed for targeted growth.
Job Titles:
- VP, Global IT, Business Systems & Digital Services
Andy joined Oxford Nanopore in 2015 leading a number of digital initiatives.
Andy is now our VP of Global IT, Digital & Business Systems. He is responsible for global information technology. His remit includes our online presence and digital channels as well as our business and manufacturing systems. Andy is also our data protection officer (DPO). He has developed our global infrastructure, introduced a robust information security & BCP framework, gained and maintained ISO27001 accreditation. One of his key achievements has been improving the customer's digital journey while driving continuous improvement across other parts of the business.
Andy is now focusing on driving growth, increased automation and efficiency in all business units, developing our data infrastructure so we're truly data-driven and evolving our digital environments to delight our customers.
Andy has previously held senior leadership positions in banking, telecommunications and professional services. He is a fellow of the BSC.
Ant Jones is VP of Engineering at Oxford Nanopore, responsible for bringing all of Nanopore?s products from concept to production; this covers Industrial design, mechanical design, electronic design, production process and equipment development and validation. Ant has 20+ years? experience mainly with-in the medical device industry taking ideas from concept to regulatory approved commercial products. Ant joined Oxford Nanopore from Lombard Medical where he was head of design developing an AAA endovascular stent graft system which has class III medical device approval worldwide. Previous to this he has designed within: IVD, Orthopeadics, automotive and Plastics industries.
Chris joined Oxford Nanopore Technologies in October 2020 from Sharp Corp, where he led the setup of Sharp Life Sciences.
Since joining Oxford Nanopore, Chris has guided the setup of subsidiary conpany structures. He will continue to lead and advise on key strategic projects and programmes for the Company, particularly looking to engage with markets beyond Life Science research tools, including potential clinical markets.
Job Titles:
- Chief Technology Officer
- Member of the Audit & Risk Committee
Clive Brown is CTO of Oxford Nanopore, where he leads the innovation of breakthrough technologies and product development, that are designed to enable the analysis of anything, by anyone, anywhere.
Clive has held a variety of roles in Genomics and Genetic R&D, he also played a key role in developing the Solexa NGS platform that is now the basis for Illumina's sequencing technology.
Dan leads the Applications Team at Oxford Nanopore Technologies. He is a highly experienced genomics scientist with expertise in all aspects of ‘next-generation' sequencing. He provides scientific and strategic leadership for multi-disciplinary teams in Oxford, New York and San Francisco. The Applications group aims to bring together sample prep technologies, genomics applications and bioinformatics, to expand the utility of Oxford Nanopore Technologies' devices and help bring the benefits of these technologies to the wider world.
Job Titles:
- Chief Executive Officer
- Member of the Audit & Risk Committee
- Member of the Executive Team
- Co - Founder of Oxford Nanopore With Spike Willcocks
Gordon Sanghera is co-founder of Oxford Nanopore with Spike Willcocks and Hagan Bayley. He was appointed CEO in May 2005 and has led the company through multiple finance rounds, and in 2021, a listing on the London Stock Exchange. The company has developed a new generation of nanopore-based sensing technology. The first products enable the real-time, high-performance, accessible and scalable analysis of DNA and RNA, and this new class of sensing has the potential to expand into proteomics and metabolomics.
Job Titles:
- Member of the Audit & Risk Committee
- Non - Executive Director
Dr Guy Harmelin has extensive experience in healthcare and technology investment and entrepreneurship. Guy was previously on the leadership team at Harel Insurance Investments and Financial Services, the largest insurance group in Israel with over $71 billion in assets under management. Guy has invested and worked with multiple successful companies including Lemonade, Innoviz, American Well, Ecoppia, Ayala Pharma, Biond Biologics, Tabit, Assured Allies, Quantum Machines, Rafael and Ein-Tal Hospitals.
Prior to joining Harel, Guy was the Co-Founder and CEO of RondinX, a computational drug target discovery Company which merged with BiomX and went public on NYSE in November 2019, PHGE.
Guy has an MD Summa Cum Laude from the University of Florence and served as a Resident Physician at the Tel Aviv Medical Center.
Dr James Clarke is responsible for the Research Division at Oxford Nanopore Technologies Ltd working with Clive Brown to push the boundaries of nanopore technology. Over the last ten years, his work has included: pioneering strand sequencing chemistry at Oxford Nanopore, scaling up the membrane chemistry for the MinION platform, and managing the companies' nanopore consortium of world class academics.
Job Titles:
- Chief Strategy Officer
- Member of the Audit & Risk Committee
After completing an MA in Chemistry and a DPhil in Biochemistry at the University of Oxford, Dr Willcocks became one of the initial members of IPGroup Plc following its landmark deal with the Chemistry Department at Oxford. Ultimately leading the Life Science team, Dr Willcocks' role encompassed all aspects of technology commercialisation, including spin-out company formation and business and corporate development, as well as private and public equity financings.
Dr Willcocks was a key player in the creation of 14 life science businesses based on technology from three universities, leading proposals for the investment of £4m in seed financing from IPGroup and holding positions of Director and Chairman for 6 portfolio companies. Working alongside the executive teams of the portfolio companies, Dr Willcocks played an integral role in out-licensing transactions, co-development deals and acquisitions. As well as supporting fundraisings for portfolio biotechnology companies, raising an aggregate of £20m, Dr Willcocks also assisted with IPGroup's own IPO in October 2003 on the LSE, raising £30m and capitalising the company at over £100m. Dr Willcocks was actively involved in the establishment of ONL whilst at IPGroup before joining full time in January 2006.
He is also a leading real tennis player, and regularly competes in international tournaments.
As the Senior Vice President of R&D - Biologics, Dr. Lakmal Jayasinghe oversees all biological research and development projects at Oxford Nanopore. Lakmal joined ONT in 2006 after finishing his PhD in chemical biology in the University of Oxford. During his PhD in the Hagan Bayley group, Lakmal has studied different nanopores and has gained a wealth of knowledge in engineering nanopores using genetic and chemical approaches. His responsibilities at ONT include improving the readout signal and performance of ONT platforms by upgrading its current nanopore reader and motor, as well as discovering new versions of nanopores, motors and chemistries to suit various ONT applications including protein sequencing. Lakmal also works with many academic collaborators across the world to ensure that Oxford Nanopore uses the best possible biological components and chemistries in its platforms.
Job Titles:
- Chairman of the Board
- Chairman of the Nomination Committee
- Member of the Audit & Risk Committee
Duncan has an extensive career on the board of many high growth international technology companies. Most recently he served as the CFO of Ocado Group plc for eight years, where he remains a senior adviser. Duncan currently sits on the board of New York Stock Exchange listed company, Cazoo Group and on the board of Trainline plc, where he serves as Chair of the Audit Committee. He also chairs the online travel agent, Loveholidays.
He has prevoiusly been CFO for other companies including Kingfisher plc, Fitness First plc and Virgin Entertainment Group. He earned a master's degree in Engineering from King's College, Cambridge in 1987. He currently serves as a trustee on the board of the Orange Tree Theatre.
Job Titles:
- in 2020 As Clinical VP
- VP, Clinical
Emma joined Oxford Nanopore in 2020 as Clinical VP. She is also our first Head of Oxford Nanopore Diagnostics (OND). In this role, she supports our ambitions for growth in healthcare applications. Emma is excited about the opportunity to grow a diagnostics business that applies technology to health care in a targeted way. Over time, this will make a huge difference to patients and their families.
Until November 2020, Emma was Director for Supplies and Innovation as part of the British government's NHS Test and Trace response to COVID-19. Prior to this, Emma was CEO of Four Eyes Insight, Chief Partnership Officer for Beacon Health Options (Northeast USA) and CEO of Beacon in the UK. Emma has also been a Commonwealth Fund Harkness Fellow in Healthcare Policy and Practice and a Senior Associate at the Institute for Strategy and Competitiveness, both at Harvard University. Prior to this, Emma was a practicing clinician in the National Health Service (NHS).
Emma holds an Executive MBA from Imperial College London, a MRCPsych from the Royal College of Psychiatrists and a Bachelor of Medicine from Southampton University.
Job Titles:
- Associate General Counsel
- Senior Director
Hannah is Senior Director, Associate General Counsel. She joined ONT in 2020, having followed our journey for several years, and was attracted by our exciting, disruptive technology and the opportunity to work for a world-changing business.
Hannah specialises in corporate law and advises ONT on a range of matters including corporate transactions, corporate governance, compliance and commercial matters.
As part of an expanding legal team, Hannah is collaborating with her legal colleagues around the world to further establish the legal team as an innovative and pragmatic partner within the business.
Hannah joined ONT from FTSE 250 intellectual property commercialisation company IP Group plc, where she provided legal services to the group and its portfolio of companies. Hannah was also company secretary for AIM-listed AI company Mirriad Advertising plc.
Hannah trained and qualified at US law firm Orrick, Herrington & Sutcliffe, where she specialised in venture capital and M&A transactions with a focus on the technology sector.
Job Titles:
- VP, Tech Transfer, Quality & Regulatory
Howard has 21 years' experience in IVD industry, including roles in product development, technology transfer and manufacturing technical support in large Corporate and start up environments. Leadership roles in establishing Design Control processes in foundation of Abbott Diabetes Care under the Consent Decree and in the first IVD CE Approval. Strong background in Design Control and Regulatory requirements.
Job Titles:
- Plant Director
- in 2014 As Our Director
- VP, Manufacturing
Jerry joined Oxford Nanopore in 2014 as our Director of Continuous Improvement. His initial deliverables were to set up our first manufacturing operation and develop a blueprint for scaling it.
Jerry is now Plant Director, and has driven the design, build and fit out of our new world class manufacturing, warehousing and logistics site, the MinION Building, in record time.
Jerry is now responsible for all aspects of our manufacturing operation. He leads an 80-strong team and is also currently planning future expansion projects in the UK and developing a regional presence for manufacturing overseas.
Jerry is looking forward to being part of the future of sequencing technology, the growth and impact of our Diagnostic technology function and playing his part in bringing products to market which have so many applications and opportunities to do good around the world.
Job Titles:
- Member of the Audit & Risk Committee
- Non - Executive Director
John O'Higgins was previously CEO of Spectris, the international productivity-enhancing instrumentation and controls company, where he led rapid global growth and evolution of the company as it pursued multiple market applications from a broad technology platform.
John holds several non-executive roles including at the global science and chemicals company Johnson Matthey plc, whose solutions are designed to enable cleaner air, improved health and the more efficient use of natural resources. He also served as a non-executive Director of Exide Technologies, the US-based supplier of battery technology to automotive and industrial users.
John is also a Member of the Corporate Advisory Board of Great Ormond Street Hospital Charity in the UK.
Job Titles:
- SVP, Corporate Development and Investor Relations
John joined Oxford Nanopore in 2019 as SVP of Corporate Development and Investor Relations.
Together with the executive leadership team, John works on a range of fundraising and partnering activities aimed at scaling the business and tapping new growth opportunities for Oxford Nanopore's technology.
Previously a Managing Director and head of the Medtech practice at Lazard, John led a broad range of strategic transactions for clients in the US, Europe and Asia. He has also worked in healthcare investment banking at J.P. Morgan in San Francisco, London and New York. John started his career at Hambrecht & Quist in San Francisco.
John holds a BA from Harvard and an MBA from INSEAD.
Jordan Herman - Chief Legal Officer, SVP
Job Titles:
- General Counsel
- SVP
- in 2021 As General Counsel
Jordan Herman joined Oxford Nanopore in 2021 as General Counsel. Prior to this Jordan was a partner at Baker Botts L.L.P., where he was our outside counsel for over a decade. He's long been involved in supporting our growth from a dozen people to a global company; from an idea to an industry leading technology.
Jordan leads our growing in-house legal team, and his responsibilities reflect our growth journey both corporately and commercially. His main remit is to ensure his team have the desire and ability to enable the company to grow, flourish and innovate while remaining legal, ethical and reflecting our values.
Jordon's role includes supporting and collaborating with leadership team, overseeing the legal department, negotiating legal transactions and identifying and managing risk. He and his team are also working on strengthening internal controls, simplifying our terms and conditions and establishing processes for global monitoring and compliance.
Jordan has many years' experience in areas including technology transfer and commercial agreements, M&A, joint ventures, licensing, and venture capital. He has worked across the life science, software, medical device and digital media industries, supporting high growth businesses in the US, Europe and around the world.
Jordan was most recently Baker Botts L.L.P., Chair of the Austin Office Corporate Department and Co-Chair of the Life Sciences group. He JD from The Ohio State University, following which he clerked for the Hon. James Rosenbaum, formerly, Chief Judge for the U.S. District Court, District of Minnesota. Jordan also has a degree in Political Economy from Washington University.
Job Titles:
- Executive
- Non Executive Director
Kate Priestman has extensive experience as a biopharma executive, serving in leadership roles across commercial, operations, corporate strategy, communications and government affairs. She is currently Chief Corporate and External Affairs Officer on the management team of global biopharma CSL, and was previously Senior Vice President of R&D Strategy, Portfolio and Operations at GSK. Kate also served on GSK's separation board, delivering the successful spin-out of Haleon plc in 2022.
In addition, Kate has held global and UK commercial leadership roles at Eli Lilly & Co and Zeneca, after an early career at the BBC, where she spent several years as a broadcaster. Kate also currently serves as a Trustee of RBG Kew, a science organisation working globally to understand plant biology and fight biodiversity loss.
Kristen has 20 years' experience in industry where biology meets informatics. including a seven-year tenure with software firm Spotfire (now part of Tibco), where she directed all aspects of its commercial partner program in life sciences.
From 2006 to 2008, Kristen served as director of informatics business development at Helicos BioSciences, and following that she served as senior director of strategic marketing and new business development at Merck's Rosetta Biosoftware business unit. She also cofounded Neotron, a developer of nuclear detection technologies, in 2009. She holds an MA and a BA in physics
Job Titles:
- VP, Commercial Market Development
Louisa joined Oxford Nanopore in 2016 and is our VP of Commercial Market Development
Louisa is a team builder who has established and grown our sales function to a global team today. She has created a sales process and a sales culture to deliver on the vision of disrupting the traditional life sciences genomics market. She's also established a senior sales leadership group, who between them manage our regional sales teams, sales development, new market development functions and sales channel partnerships.
Louisa is now responsible for leading global sales and market development teams for the company, and ensuring our technology gets out to people in all corners of the globe. She is highly motivated by the examples of impact in the field and the challenges of making cutting edge technology accessible to a global user group.
Prior to joining Oxford Nanopore, Louisa held senior sales positions of Sales at Horizon Discovery, Roche Diagnostics Australia and Source BioScience in sales roles.
Louisa is currently undertaking an Executive MBA at the Saïd Business School, University of Oxford. She holds a PhD in Molecular Biology, an honours bachelor degree in biomedical science and a Graduate Certificate in Commercialisation of Research, from Monash University.
Job Titles:
- VP, Intellectual Property
Martyn is a highly experienced patent attorney having worked mostly for US startup companies in medical diagnostic field. He is Head of IP at ONT. Martyn's technical background is in academic Chemistry/Electrochemistry BSc/Msc, and he has additional R&D Bioelectrochemistry experience
Nirmala joined Oxford Nanopore in 2020 to develop the global services team. Her remit includes leading our customer service, technical and commercial operations functions.
Nirmala initially focused on establishing regionalised customer service to serve local customers in their local time zones and languages. To this end, she onboarded three new leaders who, in turn, have been growing their teams so all are replete with the right talent, capabilities, performance metrics and training.
Nirmala works in partnership with others in senior management to ensure customer service is optimised from the root. She has also created successful business process outsourcing for some straightforward deliverables so her Oxford Nanopore teams can focus on more challenging customer issues.
Nirmala is now focused on continuing to collaborate to deliver positive customer experience, technical support for customers to drive optimal utilisation and scaling commercial operations through increased automation.
Nirmala has worked in the healthcare field since 1989 and has programme leadership and business improvement experience gained from corporate and start-up environments. Prior to joining Oxford Nanopore she worked for General Electric where she held marketing, commercial and customer experience roles within the healthcare business.
Nirmala has a PhD in Neurochemistry from the University of Cambridge and a BSc in Biochemistry from Imperial College London.
Phil joined Oxford Nanopore in 2020 having consulted for the Company since 2018.
He now heads our finance function, overseeing the department and our financial and management reporting.
Throughout the Company's fundraising in 2019 and 2020, Phil led the due diligence process liaising with potential investors and managing their advisors. Since joining full time, Phil led a major restructuring of the finance team, boosting both the size of the team and the experience within it. He will continue to oversee the preparation of accurate and timely financial information so senior leadership can make management decisions based on reliable data.
Phil has significant corporate finance experience across acquisitions, disposals and joint ventures, as well as broad commercial experience working with both the private and public sectors. Prior to joining Oxford Nanopore, he was both Managing and Finance Director of GEO Group Inc's UK subsidiary, successfully winning a number of high profile outsourcing contracts. He has also held a number of senior group finance roles at Jarvis plc, including M&A Director, and spent three years as Finance Director for a number of start-up environmental tech companies.
Phil started his career at Ernst & Young and has a BSc in Agriculture from the University of Reading.
Job Titles:
- in 2011 As Director
- VP, Operations
Rhodri joined Oxford Nanopore in 2011 as Director of Chip Production. Since 2016 he has led the Production group with responsibility for managing our technology transfer, manufacturing and quality functions and ensuring they evolve in line with our strategy.
He also offers support across our research, development and supply chain groups, contributing to solutions and providing subject matter expertise.
Looking forward, Rhodri's goals will be to continue to collaborate and communicate with colleagues, further streamline business processes, and ensure our world-leading science is commercialised and delivered with a customer-first focus.
Rhodri has been working in microengineering since 1999 and has delivered solutions to a broad range of customers across military and commercial markets. He has three patents and over 12 publications.
He has held leadership roles in material science research, product and process development, technology transfer, manufacturing and performance management. Before joining Oxford Nanopore he was Process Manager within the Sensors & Electronics Group at QinetiQ.
Rhodri has a BSc in Physics from the University of Wales.
Job Titles:
- SVP, Sales and Commercial Operations
Richard joined Oxford Nanopore in 2016 to help build our commercial team from scratch. He is now responsible for the leadership of commercial operations units including global IT, business systems, digital services, global commercial operations, technical and customer services.
His remit includes key Customer Relationship Management including leading support of the Abu Dhabi Genome Programme; the world-leading population-scale initiative to develop personalised care and personalised medicine for the region.
Richard also ensures our commercial systems, processes and teams are ready to scale and support our continued growth - drawing on experience from leading Illumina's EMEA Region, as Vice President and General Manager, prior to joining Oxford Nanopore.
At Illumina, Richard led a team of over 300 people and grew revenues by over $300m across a three-year timeframe. He also led the support of multiple population-scale sequencing programmes including Genomics England and deCODE genetics.
Richard also brings 12 years of experience as SVP and General Manager (EMEA) of Dassault Systèmes Biovia. In this role he helped commercial and research customers successfully integrate and deploy enterprise scale software solutions in research and quality/regulated environments.
Richard holds a degree in Biochemistry with Cell and Molecular Biology from the University of Birmingham.
Roger is responsible for all Informatics and IT provision at Oxford Nanopore. He started at Oxford Nanopore in the mists of time with a background in scalable web systems and NGS data management from 10 years spent at the Hinxton Genome Campus. Roger has at least one line of code in nearly every piece of software ever produced at Nanopore. Roger literally and figuratively wears hats of many different colours but routinely spends most of his waking hours converting coffee into code. Likes good software engineering practices, reading and walks in the park. Roger is easily distracted by shiny things and would rather be making stuff with buzzword compliant technology (and lasers).
Job Titles:
- SVP
- SVP, Product & Programme Management
Rosemary Sinclair Dokos, SVP of product and programme management, joined Oxford Nanopore in January 2014. Her initial role included the implementation of product management, release and distribution framework around the MinION Access Programme.
Rosemary is responsible for the management and release of all Oxford Nanopore devices, chemistry and software products. Part of this role is to ensure that teams across R&D, production, commercial and operations work together to accelerate innovation from our research teams into the hands of the customer and scale our offering to our growing user base.
Rosemary has over 15 years' experience in the life science industry. Prior to joining Oxford Nanopore, she led the Market Development and Life Science division of VWR UK where she was responsible for teams in technical sales, field marketing and contracts. In this role she worked with customers across all scientific industry sectors and managed a portfolio of over 600,000 products. Rosemary holds a BSc in Marine Sciences from the University of Southampton and is currently undertaking an executive MBA at Warwick Business School.
Sara Agee Le, PhD is VP of Global Marketing at Oxford Nanopore Technologies, having joined in July of 2021 to scale the global marketing team in line with the Company's growth ambitions.
Sara has more than 15 years of experience growing life science companies, with a strong track record of advancing market leadership and commercialization of emerging life science brands.
Most notably, Sara served as Corporate Marketing and Communications Director for 10x Genomics, a market leader in single cell and spatial genomics. Sara joined 10x Genomics in 2016 at the first launch of the Chromium Single Cell System, and held successive roles as Head of Commercial Marketing before transitioning to lead Corporate Marketing and Communications ahead of the company's IPO.
In addition to 10x, Sara held marketing leadership roles at Atomwise (VP of Marketing and Communications), Seegene Technologies (establishing US subsidiary in 2015), Bina Technologies (acquired by Roche Sequencing in 2014), and Advanced Cell Diagnostics (acquired by BioTechne in 2016 and launch of RNAscope brand).
Prior to working in the life science industry, Sara led the first K-8 curriculum initiative for ScienceBuddies, an award-winning non-profit organization furthering STEM literacy amongst K-12 students, parents, and teachers. She received her PhD in Molecular and Cell Biology from the University of California Berkeley in 2004, and her BS in Biological Sciences from the University of Denver in 1997, graduating Magna Cum Laude.
Job Titles:
- Member of the Audit & Risk Committee
- Non - Executive Director
Sarah Gordon Wild worked as a biotechnology analyst from 1983-2003. She was based on Wall Street for over 15 years and was a Management Committee Member and Senior Healthcare Analyst at Lone Pine Capital LLC from 1998 to 2003. She continues to serve on the Board of Lone Pine Capital Offshore Funds. She currently serves as a NED for Evox Therapeutics and Redx Pharma PLC and is a Partner at Duke's Auctioneers Ltd.
Job Titles:
- VP, Global Human Resources
Sarah is the VP of Global Human Resources at ONT. She started consulting for ONT in 2011 before joining full time in 2013 as our first HR hire. Her initial remit was to support the executive team on critical long-term leadership recruitment, culture creation and infrastructure development around policy, process, and communication.
From day one, Sarah's objective has been to recruit, retain and develop the best person for each role, wherever they are in the world. To this end, Sarah was instrumental in collaborating with our executive team to develop a culture imbued with our core values. Since then, we have embedded collaboration, fostered flexible working, and continue to prioritise physical and mental health, wellbeing, healthy communication and respect, all within a reward ethos.
Stuart Reid is VP of Development at Oxford Nanopore. Stuart is responsible for the specification, performance and delivery of the company's nanopore-based sensing products and applications into the marketplace. He joined Oxford Nanopore in 2006, with a particular interest in biophysical systems and signals analysis, following a DPhil in Physics (Bionanotechnology) from Oxford University as part of the Life Sciences Interface Doctoral Training Centre. He has been instrumental at all stages of the product development cycle, from the fundamental science and invention, through specification, implementation and optimisation to delivery into the hands of our user community.
Job Titles:
- Chief Financial Officer
- Member of the Audit & Risk Committee
- Financial Controller of Celltech Group Plc
- VP - Finance
A Chartered Accountant and operations specialist, Tim was interim Finance Director at Oxford Nanopore for several months in 2009, handing over a stable and well documented finance infrastructure. He then joined Oxford Nanopore as Commercial Operations Director in 2012.
In his first five years at the company Tim was responsible for setting up and managing operations and infrastructure across the company, including leading on operations for our first product launch - the MinION Access Programme - in 2015.
As part of his Operations role, Tim selected and implemented our Enterprise Resource Planning system which has remained robust and fit for purpose throughout the company's rapid growth and development.
Tim was appointed as VP-Finance in 2017 and continues to ensure that Oxford Nanopore's values of agility and entrepreneurialism are reflected in our corporate governance, risk control and business processes, to maximise business efficiency.
Having qualified as an accountant at Ernst & Young, Tim became Financial Controller of Celltech Group plc where he was a key member of the IPO team and managed several transactions of the Listed company. He went on to co-found Sterilox and ran the finance function before joining Clipper Ventures plc as Finance Director. Tim has also been Finance Director at British Biotech plc (Vernalis plc) as well as managing a portfolio of biotech and technology companies, including the AIM-listed Bioventix plc, before joining Oxford Nanopore.
Job Titles:
- Chairman of the Remuneration Committee
- Member of the Audit & Risk Committee
- Non - Executive Director
- Public Company Board Director
Wendy Becker is an experienced international, public company Board director. She is currently Chair of the global technology business Logitech International SA, a Non-executive Director of Sony Corporation and a member of the Council of the University of Oxford. She previously served on a number of boards including NHS England and Cancer Research UK. In her successful executive career, she held a number of general management, digital and marketing, and strategy roles. Wendy was CEO of Jack Wills, the British-based clothing manufacturer and retailer as well as Global CMO of Vodafone, the Managing Director of TalkTalk, and a partner at McKinsey & Company.
Job Titles:
- VP, Strategic Communications and Corporate Affairs
Zoe joined Oxford Nanopore in 2008 in a strategic marketing, communications and investor facing role - the first person to be hired with a specific commercial remit. She now leads the Company's Strategic Communications and Corporate Affairs functions, as Oxford Nanopore expands to engage with broader stakeholders, include from scientific researchers to governments and policymakers.
Since the foundation of the company she has driven accessible and authentic communities, communication channels and marketing processes and teams so that anyone engaging with, or interested in, Oxford Nanopore understands the company, our technology and our philosophy. During early commercialisation, Zoe and her team drove the creation of structures and activities that enabled the building up of Oxford Nanopore's customer community; this enables many teams at Oxford Nanopore to collaborate with our thriving user base, to improve the technology and expand the applications that it can perform. She subsequently built Marketing functions and was part of the Company's IPO team.
Zoe started her career in sales and marketing at SmithKline Beecham. She subsequently worked at the strategic marketing and communications consultancy Porter Novelli where she ran healthcare-related campaigns across a range of clinical areas for clients including GSK, BMS and Pfizer, across multiple areas including immunology, cancer, diabetes, cardiovascular and respiratory medicine.
Before joining Oxford Nanopore Zoe worked on the IPO and investor relations for a UK specialty pharma company. In 2004 she spent six months working with a medical humanitarian organisation in Sri Lanka.